Envoy Medical, Inc. Class A Common Stock (COCH) is a publicly traded Healthcare sector company. As of May 20, 2026, COCH trades at $0.73 with a market cap of $54.86M and a P/E ratio of -0.60. COCH moved +0.00% today. Year to date, COCH is +6.37%; over the trailing twelve months it is -56.47%. Its 52-week range spans $0.36 to $3.60. Analyst consensus is buy with an average price target of $2.50. Rallies surfaces COCH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Envoy Medical Secures Four Patents Covering Implantable Cochlear Systems, Battery Safety: Envoy Medical secured four patents across Australia, Europe, including Australian Patent No. 2022227537 granted July 3, 2025, and European Patent Nos. 4297848 and 4297851 granted April 8, 2026, covering cochlear signal processing and rechargeable systems. A fourth European patent No. 4297862 on thermal-dose battery charging is expected June 10, 2026.
| Metric | Value |
|---|---|
| Price | $0.73 |
| Market Cap | $54.86M |
| P/E Ratio | -0.60 |
| EPS | $-1.23 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.60 |
| 52-Week Low | $0.36 |
| Volume | 32.36K |
| Avg Volume | 0 |
| Revenue (TTM) | $241.00K |
| Net Income | $-23.76M |
| Gross Margin | -262.66% |
1 analysts cover COCH: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.50.